MEI Pharma, Inc.
(NASDAQ : MEIP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MDCOThe Medicines Co.
0.33%84.1820.1%$581.82m
AMRNAmarin Corp. Plc
0.41%21.901.7%$313.14m
VRXValeant Pharmaceuticals International, Inc.
-0.43%28.8314.1%$169.64m
BHCBausch Health Cos., Inc.
-0.43%28.830.0%$100.83m
JAZZJazz Pharmaceuticals Plc
0.98%149.552.3%$100.37m
GWPHGW Pharmaceuticals Plc
-2.61%100.826.2%$99.06m
SAGESAGE Therapeutics, Inc.
6.95%64.368.6%$76.80m
ICPTIntercept Pharmaceuticals, Inc.
-10.09%107.7016.9%$75.51m
PRGOPerrigo Co. Plc
1.22%52.446.8%$70.84m
AXSMAxsome Therapeutics, Inc.
3.35%44.692.0%$53.61m
HZNPHorizon Therapeutics Plc
1.35%32.296.6%$45.33m
ICLRICON plc
0.76%162.634.2%$44.00m
ENDPEndo International Plc
0.73%4.868.8%$35.24m
UTHRUnited Therapeutics Corp.
1.66%91.7314.3%$34.04m
MYOKMyoKardia, Inc.
0.55%67.492.1%$30.17m

Company Profile

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.